ReviewDiscover oncology2026
Adipocytes in cancer a metabolic paradox and the dawn of novel therapeutics.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In recent years, the dual regulatory role of adipocytes in the tumor microenvironment (TME) has emerged as a critical focus in cancer research. Advances in the fields of metabolic biology and tumor immunology have shown that adipocytes play a crucial role in tumor occurrence, progression, and treatment outcome by secreting adipokines, regulating metabolic reprogramming, and mediating immunosuppressive networks. This article systematically reviews the physiological functions of adipose tissue and its intricate crosstalk with cancer cells, with particular emphasis on dual metabolic and immune mechanisms by which adipocytes dynamically modulate tumor progression within the TME. Furthermore, by integrating preclinical research and translational medicine evidence, a precise treatment framework targeting the interaction between fat and tumor is proposed, providing theoretical basis for the development of metabolic immune combination therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.